comprehensive -WSS

comprehensive

author：focus 2025-09-30 09:30:13 - browse：8

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： A pediatrician calls for Congress to pass the child tax credit deal

explore

Wikipedia

WSS

Letters to First Opinion on caregivers, digital health, and more

Shifting the focus from loneliness to social health

At ASCO, AstraZeneca reports strong data for breast cancer drug

Prior authorization reform is both possible and imperative

To bolster infectious disease surveillance, genomics powerhouses team up

HIV drugs protect against transmission, even in unprotected sex

knowledge

comprehensive

hotspot

Sports medicine is finally prioritizing gender equality

Intellia reports positive results for its CRISPR

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Duchenne breakthrough therapy leaves behind pioneering families

Cord blood banking comes at a high cost to babies

Medicare details structure of new drug price negotiation program

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Wildfire smoke exposes gaps in outdoor worker protections

There's an unseen cost to disruptive road

knowledge

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

FDA endorses new sterilization method for medical devices

Maisha Meds is a PBM, but don't call it that

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

CVS is on a mission to consolidate health care. Will it work?

focus

explore

Wikipedia

entertainment